Delphi advisor to LIDDS AB (publ) in connection with a directed issue and a rights issue

Delphi has advised LIDDS AB (publ) in connection with a directed issue of approximately SEK 22.3 million and a rights issue of approximately SEK 37.1 million. The share issues have been resolved by the Board of Directors of LIDDS pursuant to the authorization granted by the Annual General Meeting on May 14, 2020. At full subscription the share issues will provide the company with approximately SEK 59.3 million before transaction costs.

LIDDS is a Swedish-based pharmaceutical company which develops new innovative pharmaceutical products with its proprietary drug delivery technology NanoZolid®. The technology is patented on the large markets in the world and offers a controlled, sustained and customized release of medication for up to six months. LIDDS shares are listed on Nasdaq First North Growth Market.

Delphi’s team consisted of Mats Dahlberg, Pekka Frölander, Jenny Lindén, Clara Jarbrand and Therese Pekkanen.